These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 7629253

  • 1. In vivo visualization of pituitary dopaminergic receptors by iodine-123 methoxybenzamide (IBZM) correlates with sensitivity to dopamine agonists in two patients with macroprolactinomas.
    Scillitani A, Dicembrino F, Di Fazio P, Vettori PP, D'Angelo V, Scarabino T, Liuzzi A.
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2523-5. PubMed ID: 7629253
    [Abstract] [Full Text] [Related]

  • 2. In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand.
    de Herder WW, Reijs AE, Kwekkeboom DJ, Hofland LJ, Nobels FR, Oei HY, Krenning EP, Lamberts SW.
    Clin Endocrinol (Oxf); 1996 Dec; 45(6):755-67. PubMed ID: 9039343
    [Abstract] [Full Text] [Related]

  • 3. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
    Colao A, Ferone D, Lastoria S, Cerbone G, Di Sarno A, Di Somma C, Lucci R, Lombardi G.
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
    [Abstract] [Full Text] [Related]

  • 4. Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas.
    Ferone D, Lastoria S, Colao A, Varrella P, Cerbone G, Acampa W, Merola B, Salvatore M, Lombardi G.
    J Clin Endocrinol Metab; 1998 Jan; 83(1):248-52. PubMed ID: 9435450
    [Abstract] [Full Text] [Related]

  • 5. Comparison of iodine-123 epidepride and iodine-123 IBZM for dopamine D2 receptor imaging in clinically non-functioning pituitary macroadenomas and macroprolactinomas.
    de Herder WW, Reijs AE, de Swart J, Kaandorp Y, Lamberts SW, Krenning EP, Kwekkeboom DJ.
    Eur J Nucl Med; 1999 Jan; 26(1):46-50. PubMed ID: 9933661
    [Abstract] [Full Text] [Related]

  • 6. Iodine-123-IBZM-SPECT: studies in 15 patients with pituitary tumors.
    Pirker W, Brücke T, Riedl M, Clodi M, Luger A, Asenbaum S, Podreka I, Deecke L.
    J Neural Transm Gen Sect; 1994 Jan; 97(3):235-44. PubMed ID: 7873131
    [Abstract] [Full Text] [Related]

  • 7. Receptor imaging with 111In-pentreotide and 123I-methoxybenzamide, and inhibition tests with octreotide and bromocriptine of mixed growth hormone/prolactin-secreting pituitary tumors.
    Panza N, Rambaldi PF, Battista C, Ambrosio G, Cascini GL, Schillirò F, Mansi L.
    Biomed Pharmacother; 1999 Aug; 53(7):319-22. PubMed ID: 10472432
    [Abstract] [Full Text] [Related]

  • 8. Dopamine D2 receptor imaging in pituitary adenomas using iodine-123-epidepride and SPECT.
    Pirker W, Riedl M, Luger A, Czech T, Rössler K, Asenbaum S, Angelberger P, Kornhuber J, Deecke L, Podreka I, Brücke T.
    J Nucl Med; 1996 Dec; 37(12):1931-7. PubMed ID: 8970508
    [Abstract] [Full Text] [Related]

  • 9. Imaging of dopamine D2 and somatostatin receptors in vivo using single-photon emission tomography in a patient with a TSH/PRL-producing pituitary macroadenoma.
    Verhoeff NP, Bemelman FJ, Wiersinga WM, van Royen EA.
    Eur J Nucl Med; 1993 Jun; 20(6):555-61. PubMed ID: 8339737
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Differential accumulation of iodine-123-iodobenzamide in melanotic and amelanotic melanoma metastases in vivo.
    Larisch R, Schulte KW, Vosberg H, Ruzicka T, Müller-Gärtner HW.
    J Nucl Med; 1998 Jun; 39(6):996-1001. PubMed ID: 9627332
    [Abstract] [Full Text] [Related]

  • 13. Primary medical therapy of micro- and macroprolactinomas in men.
    Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS, Klibanski A.
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
    [Abstract] [Full Text] [Related]

  • 14. [Disappearance of the radiographic image of a macroprolactinoma after treatment with bromocriptine].
    Forsbach G, Olivares F, Vázquez J, Güitrón A.
    Ginecol Obstet Mex; 1998 Apr; 66():170-2. PubMed ID: 9617019
    [Abstract] [Full Text] [Related]

  • 15. Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796.
    Seibyl JP, Zea-Ponce Y, Brenner L, Baldwin RM, Krystal JH, Offord SJ, Mochoviak S, Charney DS, Hoffer PB, Innis RB.
    J Nucl Med; 1996 Jan; 37(1):11-5. PubMed ID: 8543979
    [Abstract] [Full Text] [Related]

  • 16. Resistance to bromocriptine in prolactinomas.
    Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, Kordon C, Peillon F, Jaquet P, Enjalbert A.
    J Clin Endocrinol Metab; 1989 Sep; 69(3):500-9. PubMed ID: 2760167
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. In vivo SPECT imaging of CNS D-2 dopamine receptors: initial studies with iodine-123-IBZM in humans.
    Kung HF, Alavi A, Chang W, Kung MP, Keyes JW, Velchik MG, Billings J, Pan S, Noto R, Rausch.
    J Nucl Med; 1990 May; 31(5):573-9. PubMed ID: 2140408
    [Abstract] [Full Text] [Related]

  • 20. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine.
    Brue T, Pellegrini I, Gunz G, Morange I, Dewailly D, Brownell J, Enjalbert A, Jaquet P.
    J Clin Endocrinol Metab; 1992 Mar; 74(3):577-84. PubMed ID: 1346788
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.